NCT03568890View on ClinicalTrials.gov

Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

510

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

August 1, 2025

Study Completion Date

September 1, 2030

Conditions
Left Atrial Appendage ClosureThrombosisStrokeTIABleeding
Interventions
DRUG

Rivaroxaban, dabigatran, apixaban, or edoxaban

Duration of treatment: 60 days

DRUG

Clopidogrel -75 mg/day

Duration of treatment: 60 days

DRUG

Low dose aspirin -80 to 125 mg/day-

Duration of treatment: 60 days

Trial Locations (1)

G1V 4G5

Josep Rodes-Cabau, Québec

All Listed Sponsors
lead

Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec

OTHER